Last mentioned: Feb 27, 2026
Anticipated Milestones
Expected expansion of WRBY's insurance network and SEER's multi-omics software updates.
Market Analysis
Analysts highlight the shift toward integrated health platforms in both consumer and clinical sectors.
Q4 Earnings Calls
Warby Parker and Seer, Inc. both report year-end results, outlining 2026 growth strategies.
Warby Parker and Seer, Inc. reported Q4 2025 results, highlighting a pivot toward integrated health platforms and advanced diagnostic capabilities. While Warby Parker expands its telehealth and physical eye care ecosystem, Seer is accelerating the commercialization of its proteomics technology to redefine precision medicine.
This page surfaces every story mentioning Omid Farokhzad across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Omid Farokhzad was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |